Brief: Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations In Combination With Radiation Therapy

Kazia Therapeutics

06/07/2023 12:12

July 6 (Reuters) - Kazia Therapeutics Ltd  KZA.AX :
    * KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA
FOR
TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY
MUTATIONS IN COMBINATION WITH RADIATION THERAPY
    * KAZIA THERAPEUTICS LTD - FURTHER DATA FROM ONGOING PHASE 1
STUDY
IS EXPECTED IN 1Q CY2024

Source text for Eikon:  ID:nPn5fdwNa 
Further company coverage:  KZA.AX 

 (Reuters.Briefs@thomsonreuters.com)